[go: up one dir, main page]

DK1539742T3 - Indolderivater, der er nyttige som histamin H3-antagonister - Google Patents

Indolderivater, der er nyttige som histamin H3-antagonister

Info

Publication number
DK1539742T3
DK1539742T3 DK03761216T DK03761216T DK1539742T3 DK 1539742 T3 DK1539742 T3 DK 1539742T3 DK 03761216 T DK03761216 T DK 03761216T DK 03761216 T DK03761216 T DK 03761216T DK 1539742 T3 DK1539742 T3 DK 1539742T3
Authority
DK
Denmark
Prior art keywords
histamine
antagonists
indole derivatives
derivatives useful
useful
Prior art date
Application number
DK03761216T
Other languages
English (en)
Inventor
Robert G Aslanian
Michael Y Berlin
Pietro Mangiaracina
Kevin D Mccormick
Mwangi W Mutahi
Stuart B Rosenblum
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1539742T3 publication Critical patent/DK1539742T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK03761216T 2002-06-24 2003-06-20 Indolderivater, der er nyttige som histamin H3-antagonister DK1539742T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39098702P 2002-06-24 2002-06-24

Publications (1)

Publication Number Publication Date
DK1539742T3 true DK1539742T3 (da) 2006-12-27

Family

ID=30000654

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03761216T DK1539742T3 (da) 2002-06-24 2003-06-20 Indolderivater, der er nyttige som histamin H3-antagonister

Country Status (21)

Country Link
US (1) US6951871B2 (da)
EP (2) EP1539742B1 (da)
JP (1) JP4326468B2 (da)
KR (1) KR20050009757A (da)
CN (1) CN100497334C (da)
AR (1) AR039718A1 (da)
AT (1) ATE344798T1 (da)
AU (1) AU2003243709B2 (da)
CA (1) CA2489337C (da)
CY (1) CY1105986T1 (da)
DE (1) DE60309598T2 (da)
DK (1) DK1539742T3 (da)
ES (1) ES2271644T3 (da)
IL (1) IL165863A0 (da)
MX (1) MXPA05000193A (da)
MY (1) MY135686A (da)
NZ (1) NZ537200A (da)
PT (1) PT1539742E (da)
TW (1) TW200400031A (da)
WO (1) WO2004000831A1 (da)
ZA (1) ZA200410213B (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
DK1556354T3 (da) * 2002-06-28 2008-06-02 Euro Celtique Sa Terapeutiske piperazinderivater, der er egnede til behandling af smerter
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
AU2005264988B2 (en) 2004-06-17 2011-09-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
PL1761519T3 (pl) 2004-06-21 2008-09-30 Hoffmann La Roche Pochodne indolu jako antagoniści receptorów histaminowych
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
MX2007006764A (es) * 2004-12-06 2007-08-15 Aventis Pharma Sa Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
FR2878849B1 (fr) * 2004-12-06 2008-09-12 Aventis Pharma Sa Indoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2006077024A2 (en) 2005-01-19 2006-07-27 F. Hoffmann-La Roche Ag 5-aminoindole derivatives
US7635705B2 (en) * 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
CA2609957A1 (en) 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
WO2007016496A2 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP1931665A1 (en) 2005-09-20 2008-06-18 Schering Corporation 1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine useful as histamine h3 antagonist
AR056690A1 (es) * 2005-10-14 2007-10-17 Athersys Inc Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
ATE485294T1 (de) * 2005-11-18 2010-11-15 Hoffmann La Roche Azaindol-2-carboxamid-derivate
ES2342979T3 (es) * 2005-11-30 2010-07-20 F. Hoffmann-La Roche Ag Derivados de indol-2-carboxamida sustituidos en 5.
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
AR058558A1 (es) * 2005-12-21 2008-02-13 Schering Corp Derivados de anilina sustituida utiles como antagonistas de la histamina h3
CN101378807A (zh) * 2005-12-21 2009-03-04 先灵公司 H3拮抗剂/反相激动剂与食欲抑制剂的组合
CA2634250A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
US7696229B2 (en) * 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
US7514433B2 (en) * 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
CA2667547C (en) * 2006-10-27 2014-07-29 Boehringer Ingelheim International Gmbh Piperidyl-propane-thiol ccr3 modulators
ATE524461T1 (de) 2006-10-27 2011-09-15 Boehringer Ingelheim Int Neue substituierte piperidylpropanthiole
EP2184990A4 (en) * 2007-08-15 2011-10-19 Memory Pharm Corp 3'-SUBSTITUTED COMPOUNDS WITH 5-HT6 RECEPTOR AFFINITY
WO2009089134A1 (en) * 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
WO2009158375A1 (en) * 2008-06-25 2009-12-30 Abbott Laboratories Aza-cylic indole- 2 -carboxamides and methods of use thereof
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US20110130385A1 (en) * 2008-07-23 2011-06-02 De Lera Ruiz Manuel Bicyclic Heterocylic Derivatives and Methods of Use
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JP5787977B2 (ja) 2010-04-08 2015-09-30 レスピバート・リミテツド P38mapキナーゼ阻害剤
KR20130087002A (ko) 2010-06-04 2013-08-05 알바니 몰레큘라 리써치, 인크. 글리신 수송체-1 저해제, 그의 제조 방법 및 그의 용도
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Fxr有限責任公司 含有雙環核心部分之新穎lxr調節劑
EP3797769A1 (fr) 2019-09-25 2021-03-31 Fontès, M. Michel Composition a usage therapeutique
CA3159988C (en) 2020-07-15 2023-09-19 Bernard Schachtel Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0730037B2 (ja) 1987-03-13 1995-04-05 第一製薬株式会社 ピリミジニルプロピオン酸誘導体
DK181190D0 (da) 1990-07-30 1990-07-30 Lundbeck & Co As H 3-aryl-indol- eller 3-aryl-indazolderivater
US5352707A (en) * 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
PT888336E (pt) * 1996-02-21 2002-12-31 Aventis Pharma Inc Novas n-metil-n-(4-(4-(1h-benzimidazol-2-il-amino)-piperidina-1-il)-2-(aril)-butil)-benzamidas substituidas uteis para o tratamento de doencas alergicas
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
TWI221768B (en) 1996-08-16 2004-10-11 Schering Corp Pharmaceutical composition comprising histamine H1 receptor antagonist and histamine H3 receptor antagonist providing nasal decongestant effect
ES2225998T3 (es) * 1996-11-25 2005-03-16 THE PROCTER & GAMBLE COMPANY Compuestos (2-imidazolinilamino)indol utiles como agonistas del adrenorreceptor alfa 2.
US5869479A (en) * 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
ES2259619T3 (es) 1999-12-20 2006-10-16 Eli Lilly And Company Derivados de indol para el tratamiento de depresion y ansiedad.
PE20020507A1 (es) 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
ES2172436B1 (es) * 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
CA2436083A1 (en) * 2001-02-08 2002-09-19 Schering Corporation Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders
US6849621B2 (en) * 2001-03-13 2005-02-01 Schering Corporation Piperidine compounds

Also Published As

Publication number Publication date
JP2005531615A (ja) 2005-10-20
IL165863A0 (en) 2006-01-15
TW200400031A (en) 2004-01-01
CY1105986T1 (el) 2011-04-06
CN100497334C (zh) 2009-06-10
MXPA05000193A (es) 2005-04-08
DE60309598D1 (de) 2006-12-21
US20040019099A1 (en) 2004-01-29
MY135686A (en) 2008-06-30
NZ537200A (en) 2007-09-28
EP1539742A1 (en) 2005-06-15
ES2271644T3 (es) 2007-04-16
DE60309598T2 (de) 2007-09-13
EP1539742B1 (en) 2006-11-08
WO2004000831A1 (en) 2003-12-31
CA2489337C (en) 2010-05-25
CA2489337A1 (en) 2003-12-31
JP4326468B2 (ja) 2009-09-09
AU2003243709B2 (en) 2007-01-18
CN1662524A (zh) 2005-08-31
US6951871B2 (en) 2005-10-04
AU2003243709A1 (en) 2004-01-06
EP1777223A1 (en) 2007-04-25
AR039718A1 (es) 2005-03-09
PT1539742E (pt) 2007-01-31
ATE344798T1 (de) 2006-11-15
KR20050009757A (ko) 2005-01-25
ZA200410213B (en) 2005-10-20
HK1072259A1 (en) 2005-08-19

Similar Documents

Publication Publication Date Title
DK1539742T3 (da) Indolderivater, der er nyttige som histamin H3-antagonister
DK1499316T3 (da) (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
DK1501787T3 (da) N-biphenylmethylaminocycloalkancarboxamid-derivater med en substituerent på methyl, der er nyttige som bradykininantagonister
DK2279737T3 (da) Heterocycliske forbindelser, der er aktive som beta-lactamaseinhibitorer
LTC1663996I2 (lt) (Tio)karbamoil-cikloheksano dariniai kaip D3/D2 receptorių antagonistai
DK1571145T3 (da) Substitueret piperidinforbindelser til anvendelse som H3 histaminreceptor-antagonister
DK1385825T3 (da) Substituerede 2-pyridincyclohexan-1,4-diaminderivater
DK1175401T3 (da) Piperazinderivater, der er nyttige som CCR5-antagonister
DK1490355T3 (da) Indolylmaleimidderivater
DK1562595T3 (da) Diarylethere som opioidreceptorantagonister
NO20052797D0 (no) Fenyl eller heteroaryl aminoalkanderivater som IP-reseptorantagonister
DK1175402T3 (da) Piperidinderivater, der er nyttige som CCR5-antagonister
DK1551511T5 (da) Heterocykliske aromatiske forbindelser, der er anvendelige som væksthormonsekretagoger
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
IS7607A (is) Ný útskipt indól
DK1501826T3 (da) Substituerede indoler som alpha-1-agonister
ATE384053T1 (de) Triazolderivate als tachykininrezeptor- antagonisten
DK1668014T3 (da) Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer
ZA200410408B (en) N-substituted piperidine derivatives as serotonin receptor agents.
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
DE602004024770D1 (de) Substituierte 8-perfluoro-6,7,8,9-tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
DK1360184T3 (da) Piperidinderivater som neurokinin-1-antagonister
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1636206T3 (da) Imidazolderivater som glutamatreceptorantagonister